Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Addendum „Antivirale Therapie der chronischen Hepatitis-D-Virusinfektion“ zur S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS).
Sandmann L, Berg T, Deterding K, Fischer N, Hinrichsen H, Petersen J, Tacke F, Cornberg M; Collaborators. Sandmann L, et al. Z Gastroenterol. 2023 Dec;61(12):1635-1653. doi: 10.1055/a-2181-3046. Epub 2023 Dec 11. Z Gastroenterol. 2023. PMID: 38081179 Free article. German. No abstract available.
Antiviral Therapy of Chronic Hepatitis D Virus Infection - Addendum to the S3 Guideline "Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection" of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS).
Sandmann L, Berg T, Deterding K, Fischer N, Hinrichsen H, Petersen J, Tacke F, Cornberg M; Collaborators. Sandmann L, et al. Z Gastroenterol. 2023 Dec;61(12):e715-e732. doi: 10.1055/a-2181-3345. Epub 2023 Dec 11. Z Gastroenterol. 2023. PMID: 38081178 No abstract available.
A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
van Bömmel F, Stein K, Heyne R, Petersen J, Buggisch P, Berg C, Zeuzem S, Stallmach A, Sprinzl M, Schott E, Pathil-Warth A, von Arnim U, Keitel V, Lohmeyer J, Simon KG, Trautwein C, Trein A, Hüppe D, Cornberg M, Lammert F, Ingiliz P, Zachoval R, Hinrichsen H, Zipprich A, Klinker H, Schulze Zur Wiesch J, Schmiedeknecht A, Brosteanu O, Berg T. van Bömmel F, et al. Among authors: klinker h. J Hepatol. 2023 May;78(5):926-936. doi: 10.1016/j.jhep.2022.12.018. Epub 2023 Mar 28. J Hepatol. 2023. PMID: 37062574 Free article. Clinical Trial.
Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib.
Zimmermann S, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Gesierich A, Schilling B, Kalogirou C, Goebeler ME, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O. Zimmermann S, et al. Among authors: klinker h. J Pharm Biomed Anal. 2023 May 10;228:115311. doi: 10.1016/j.jpba.2023.115311. Epub 2023 Feb 23. J Pharm Biomed Anal. 2023. PMID: 36841066
[Development and validation of potential structure indicators for clinical infectious disease (ID) care in German hospitals during the COVID-19 pandemic].
Tscharntke L, Stecher M, Classen AY, Jung N, Eberwein L, Friedrichs A, Klinker H, Schons MJ, Spinner CD, J G T Vehreschild M, de With K, Vehreschild JJ. Tscharntke L, et al. Among authors: klinker h. Z Evid Fortbild Qual Gesundhwes. 2023 Feb;176:12-21. doi: 10.1016/j.zefq.2022.11.005. Epub 2023 Feb 6. Z Evid Fortbild Qual Gesundhwes. 2023. PMID: 36754716 Free PMC article. Review. German.
A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients.
Gerner B, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Zimmermann S, Kurlbaum M, Klinker H, Isberner N, Scherf-Clavel O. Gerner B, et al. Among authors: klinker h. Pharmaceutics. 2022 Nov 22;14(12):2556. doi: 10.3390/pharmaceutics14122556. Pharmaceutics. 2022. PMID: 36559050 Free PMC article.
Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma.
Isberner N, Gesierich A, Balakirouchenane D, Schilling B, Aghai-Trommeschlaeger F, Zimmermann S, Kurlbaum M, Puszkiel A, Blanchet B, Klinker H, Scherf-Clavel O. Isberner N, et al. Among authors: klinker h. Cancers (Basel). 2022 Sep 20;14(19):4566. doi: 10.3390/cancers14194566. Cancers (Basel). 2022. PMID: 36230489 Free PMC article.
DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.
Madurka I, Vishnevsky A, Soriano JB, Gans SJ, Ore DJS, Rendon A, Ulrik CS, Bhatnagar S, Krishnamurthy S, Mc Harry K, Welte T, Fernandez AA, Mehes B, Meiser K, Gatlik E, Sommer U, Junge G, Rezende E; Study group. Madurka I, et al. Infection. 2023 Jun;51(3):641-654. doi: 10.1007/s15010-022-01904-w. Epub 2022 Sep 14. Infection. 2023. PMID: 36104613 Free PMC article. Clinical Trial.
220 results